Decoy Therapeutics (NASDAQ:DCOY) Issues Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) posted its quarterly earnings results on Wednesday. The company reported ($4.46) EPS for the quarter, FiscalAI reports.

Decoy Therapeutics Trading Down 7.0%

NASDAQ:DCOY traded down $0.27 on Wednesday, hitting $3.60. 24,249 shares of the stock were exchanged, compared to its average volume of 182,489. The stock has a market cap of $2.12 million, a PE ratio of -0.03 and a beta of 0.64. The stock has a fifty day moving average of $5.69 and a 200-day moving average of $6.69. Decoy Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $95.02.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.